Articles

Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; University of Melbourne, Parkville, Victoria, Australia; Royal Melbourne Hospital, Parkville, Victoria, Australia; St Vincent’s Hospital Melbourne, Fitzroy, Victoria
Medical University of Lodz, Lodz
Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano
Washington University School of Medicine, St Louis, MO
Peninsula Private Hospital, Frankston, Victoria
Calvary Mater Newcastle, Waratah, NSW
North Shore Hospital, Auckland
Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA
Department of Haematology, Christchurch Hospital, Christchurch
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome
Monash Health, Clayton, Victoria, Australia; Monash University, Clayton, Victoria
Hematology Unit, Santa Maria delle Croci Hospital, Ravenna
Copernicus Wojewódzkie Centrum Onkologii, Gdánsk
Concord Repatriation General Hospital, Concord, NSW, Australia; University of Sydney, Concord, NSW
Fourth Department of Internal Medicine - Hematology, University Hospital, Hradec Kralove, Czech Republic; Faculty of Medicine, Charles University, Prague, Czech Republic
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Hematology, Karolinska University Hospital, Stockholm
First Department of Medicine, First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic
ASST Grande Ospedale Metropolitano Niguarda, Milan
BeiGene USA, Inc., San Mateo, CA
BeiGene USA, Inc., San Mateo, CA
BeiGene USA, Inc., San Mateo, CA
BeiGene USA, Inc., San Mateo, CA
BeiGene USA, Inc., San Mateo, CA
BeiGene USA, Inc., San Mateo, CA
St James’s University Hospital, Leeds
Dana-Farber Cancer Institute, Boston, MA
Haematologica Early view Oct 13, 2020 https://doi.org/10.3324/haematol.2020.259432